T

    Tscan Therapeutics Inc (TCRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.73
    -0.02 (-3.16%)

    Market Cap: $49.46M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    +3.90%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.25 - $-0.19
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate Drift
    90d ago$-0.22-0.8%
    60d ago$-0.19+12.8%
    30d ago$-0.19+12.8%
    7d ago$-0.21+0.0%
    Current$-0.21
    Revenue Consensus
    $2M
    Range$2M - $3M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.29
    Range$-0.33 - $-0.20
    4 analysts
    Revenue Consensus
    $-1145280
    Range$-5300330 - $4M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.29---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 11
    		$-0.23$-0.29+20.69%Beat+17.9%
    Mar 26
    Reported May 6
    		$-0.22$-0.16-37.50%Miss+15.4%
    Dec 25
    Reported Mar 4
    		$-0.18$-0.27+32.61%Beat+40.0%
    Sep 25
    Reported Nov 12
    		$-0.28$-0.33+15.15%Beat-12.0%
    Jun 25
    Reported Aug 12
    		$-0.28$-0.32+12.50%Beat+0.0%
    Mar 25
    Reported May 6
    		$-0.26$-0.28+7.14%Beat+18.8%
    Dec 24
    Reported Mar 5
    		$-0.30$-0.29-3.45%Miss-42.9%
    Sep 24
    Reported Nov 12
    		$-0.25$-0.29+13.79%Beat-4.2%
    Jun 24
    Reported Aug 12
    		$-0.28$-0.28+0.00%Beat+45.1%
    Mar 24
    Reported May 13
    		$-0.32$-0.24-33.33%Miss+65.6%
    Dec 23
    Reported Mar 6
    		$-0.21$-0.29+27.59%Beat+73.1%
    Sep 23
    Reported Nov 9
    		$-0.24$-0.44+45.45%Beat+64.2%
    Jun 23
    Reported Aug 10
    		$-0.51$-0.78+34.62%Beat+19.0%
    Mar 23
    Reported May 10
    		$-0.93$-0.75-24.00%Miss-38.8%
    Dec 22
    Reported Mar 8
    		$-0.78$-0.70-11.43%Miss-105.3%
    Sep 22
    Reported Nov 9
    		$-0.67$-0.71+5.63%Beat+16.3%
    Jun 22
    Reported Aug 10
    		$-0.63$-0.72+12.50%Beat+91.8%
    Mar 22
    Reported May 9
    		$-0.67$-0.62-8.06%Miss+39.6%
    Dec 21
    Reported Mar 9
    		$-0.38$-0.73+47.95%Beat-
    Sep 21
    Reported Nov 10
    		$-0.80$-0.48-66.67%Miss-
    Jun 21
    Reported Jul 15
    		$-7.69$-4.09-88.02%Miss-
    Mar 21
    Reported Apr 30
    		$-1.11N/A+82.66%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.80EV/EBITDA0.39x
    Price/FCF-0.80xFCF Yield-124.90%
    Profitability
    Profit Margin0.00%Operating Margin-2901.00%
    ROE-95.80%ROIC-93.55%
    Financial Health
    Debt/Equity0.47xInterest Coverage-43.22x
    Current Ratio3.37xQuick Ratio3.37x
    Trading Statistics
    Beta1.07Avg Volume314.85K
    52-Week High$2.5752-Week Low$0.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.77
    SMA 20$0.77
    SMA 50$0.86
    SMA 200$1.01
    EMA 10$0.77
    EMA 20$0.78
    EMA 50$0.85
    EMA 200$1.08

    MACD

    Line: -0.03Signal: -0.03Hist: 0.00

    ADX

    ADX: 11.5+DI: 13.1-DI: 20.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down24.0
    PSAR$0.83

    Bollinger Bands

    Upper Band$0.82
    Lower Band$0.73
    %B Position1150%(Upper)
    Band Width0.01

    RSI (14-Day)

    Neutral
    39.0

    Momentum Oscillators

    Stoch %K9.6
    Stoch %D21.1
    Williams %R-93.5
    ROC (10d)-6.9%
    Momentum-0.05
    CCI (20d)-199.9
    MFI (14d)34.8

    Volatility Measures

    ATR (14d)$0.05(6.6%)
    StdDev (20d)0.02
    Hist Vol55.6%(High)

    Volume Flow

    VWAP$0.74
    OBV-10.6M
    AD Line-20.0M
    CMF (20d)-0.087

    Volume Metrics

    Avg Vol (20d)308.5K
    Vol Ratio1.1x
    VWMA (20d)$0.77

    Pivot Points

    R3$0.80
    R2$0.79
    R1$0.77
    Pivot Point$0.76
    S1$0.74
    S2$0.73
    S3$0.71

    Advanced Oscillators

    TSI-14.25
    Ultimate Osc35.5
    KST-96.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.05M$982,000$2.57M$2.51M$3.08M$2.17M$665,000$1.05M$536,000$566,000$7.21M$3.89M
    Cost of Revenue$0$0$723,000$0$0$0$711,000$0$0$0$1.28M$0
    Gross Profit$1.05M$982,000$2.57M$2.51M$3.08M$2.17M$665,000$1.05M$536,000$566,000$7.21M$3.89M
    Operating Expenses$31.54M$30.12M$26.43M$39.56M$41.73M$38.42M$37.38M$33.67M$34.65M$31.94M$28.57M$28.64M
    R&D$23.40M$21.90M$20.04M$31.69M$32.63M$29.79M$29.35M$26.26M$26.88M$24.86M$22.41M$22.74M
    SG&A$8.14M$8.22M$6.39M$7.87M$9.10M$8.63M$8.02M$7.41M$7.77M$7.08M$6.16M$5.89M
    Operating Income$-30,493,000$-29,139,000$-23,858,000$-37,052,000$-38,653,000$-36,250,000$-36,712,000$-32,622,000$-34,114,000$-31,373,000$-21,357,000$-24,748,000
    Interest Income$833,000$1.16M$1.58M$2.04M$2.39M$2.80M$2.78M$3.69M$3.40M$2.19M$2.60M$2.73M
    Interest Expense$699,000$689,000$702,000$699,000$689,000$679,000$1.87M$958,000$952,000$959,000$852,000$982,000
    Income Before Tax$-30,359,000$-28,666,000$-22,977,000$-35,710,000$-36,952,000$-34,127,000$-35,809,000$-29,887,000$-31,661,000$-30,142,000$-19,613,000$-22,997,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-30,359,000$-28,666,000$-22,977,000$-35,710,000$-36,952,000$-34,127,000$-35,809,000$-29,887,000$-31,661,000$-30,142,000$-19,613,000$-22,997,000
    EBITDA$-29,794,000$-28,446,000$-23,135,000$-36,285,000$-37,955,000$-35,572,000$-36,001,000$-31,595,000$-32,998,000$-30,119,000$-20,077,000$-23,462,000
    EBIT$-30,493,000$-29,139,000$-23,858,000$-37,052,000$-38,653,000$-36,250,000$-36,712,000$-32,622,000$-34,114,000$-31,373,000$-21,357,000$-24,748,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TCRX

    News

    Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones

    Amgen has terminated its research collaboration and license agreement with TScan Therapeutics, effectively removing over $500 million in potential milestone payments for TScan. The agreement, originally signed in May 2023, focused on using TScan's platform to identify antigens for Crohn's disease, with Amgen holding exclusive development rights. TScan will retain all licenses, and its primary focus remains its oncology-focused TCR-T pipeline, which recently dosed its first patient in a Phase III trial.

    AllSci•8/20/26•
    Bearish

    TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing

    Amgen has decided to terminate its research collaboration and license agreement with TScan Therapeutics. This information was disclosed via an SEC filing. The full details of this termination can be found in the mentioned SEC filing.

    TradingView•8/18/26•
    Neutral

    Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants

    The Biotechnology Value Fund (BVF) group and its affiliates have disclosed a 9.99% ownership stake in TScan Therapeutics (TCRX) as of June 30, 2026. This aggregate beneficial ownership includes 6,417,831 shares of Voting Common Stock, a significant portion of which are Pre-Funded Warrants exercisable at $0.0001 per share. The warrants are subject to a 9.99% beneficial ownership blocker, limiting current exercisability to 853,541 underlying shares.

    Stock Titan•8/14/26•
    Neutral

    Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock

    Lynx1 Capital Management LP and Weston Nichols have disclosed a 13.1% beneficial ownership stake in TScan Therapeutics (TCRX) common stock, totaling 20,519,148 shares. This ownership represents shared voting and dispositive power, with the Lynx1 Fund retaining rights to dividends and sale proceeds. The filing is an amendment to a Schedule 13G and is based on 61,074,229 shares outstanding as of May 1, 2026.

    Stock Titan•8/14/26•
    Neutral

    H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy

    H.C. Wainwright has reiterated a buy rating and a $7.00 price target for Tscan Therapeutics (NASDAQ:TCRX) following promising initial data from its Phase 1 ALLOHA-1 study. The biotech company, currently trading near its 52-week low, demonstrated significant patient response in the study and is moving forward with a Phase 3 trial. Tscan Therapeutics is also exploring automated manufacturing processes through a collaboration with Cellares.

    Investing.com•8/14/26•
    Bullish

    Frequently Asked Questions About TCRX

    Does TCRX pay dividends?
    Tscan Therapeutics Inc (TCRX) does not currently pay a regular dividend.
    What is TCRX's market cap?
    Tscan Therapeutics Inc (TCRX) has a market capitalization of $49.46M with a current stock price of $0.73.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In